Recombinant Human Thrombopoietin Efficacy in Chronic Liver Disease Patients

Henan Provincial People's Hospital retrospective study of 259 patients with chronic liver disease-associated thrombocytopenia treated with recombinant human thrombopoietin from January 2021 to October 2023. The dataset compares clinical outcomes between patients with and without concomitant infections, analyzing response rates, time to response, and platelet transfusion requirements.

Use Cases

• Analyze response rates and time to response for thrombopoietin treatment segmented by concomitant infection status.
• Model the relationship between Child-Pugh score, cirrhosis status, and treatment efficacy using multivariable analysis results.
• Compare platelet transfusion rates between infection and non-infection patient groups to assess treatment burden.

Strengths

• Clinical data from 259 patients provides a substantive cohort for analysis.
• Study covers a defined time range from January 2021 to October 2023.
• Propensity score matching was applied to adjust for baseline confounders, improving comparability.

Limitations

• Small dataset size (15.6 KB) indicates limited scope, likely containing summary statistics rather than patient-level records.
• Data is from a single hospital (Henan Provincial People's Hospital), limiting geographic and institutional generalizability.
• Retrospective study design is subject to inherent biases compared to a prospective trial.

Provenance

Source

Xun Wei via figshare.

Collection Method

Retrospective study of patient medical records.

Time Range

January 2021 to October 2023.

Freshness

Last updated March 2026.

Geography

Henan Provincial People's Hospital, China.